The Development Office’s Corporate and Foundation (C&F) Team identified the below funding opportunities. To apply, please contact DevCorpFound@mountsinai.org. The C&F team will help plan, write, and submit your application.
| American Society of Transplantation: Transition to Independence Research Grants | Amount: Up to $150,000 over 2 years | Deadline: June 15, 2026 | Eligibility: The applicant (MD, PhD, PharmD, or equivalent) must hold an academic faculty appointment and be developing an independent research program Applicants cannot be a PI on a previous or current NIH grant to perform independent research. Applications are accepted in basic, clinical, and translational research. Only applications supporting research directly related to solid organ transplantation will be considered. |
About: The purpose of the AST Research Network Transition to Independence Research Grants is to promote the careers of academic investigators whose development of an independent research program is focused on the field of basic science, translational and clinical investigation in solid organ transplantation. The grants are intended to provide support for the investigator’s transition to an R-series or equivalent grant. The Transition to Independence Research Grant seeks to: •Foster the transition of early to mid-career scientists who are contributing to our understanding of transplant science/immunobiology and/or treatment of transplant recipients and need funding to start or strengthen work that is not yet funded by larger grants. •Foster research that is of high merit. •Encourage the continued commitment of high-quality applicants to careers in academic transplantation About: Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience. |
https://www.myast.org/grant-opportunities/transition-independence-grants |
| Glaucoma Research Foundation: Shaffer Grant for Innovative Research | Amount: Up to $55,000 over 1 year | Deadline: • LOI due July 15, 2026 • Full proposal deadline TBD |
Eligibility: • Grant applicants must possess a graduate degree • Must not have received a Shaffer Grant within the prior three years |
About: Supports young investigators with new perspectives to treat and cure glaucoma. There are two primary focus areas that this grant will fund: 1.Physiology of Glaucoma: May include projects to protect and restore the optic nerve, accurately detect glaucoma and monitor its progress, provide better understanding and treatment for congenital/juvenile glaucoma, understand the intraocular pressure system and develop better treatments, and determine the risk factors for glaucoma damage using systematic outcomes data. 2.Genetics of Glaucoma: May include projects to identify the genes that cause glaucoma and explore new approaches to gene therapy to preserve or restore vision |
Apply For A Grant – Glaucoma Research Foundation |
| LAM Foundation Clinical Research Grant | Amount: $50,000 over 1 years | Deadline: •LOI due June 15, 2026 •Full proposal due September 15, 2026 |
Eligibility: •An applicant may be a clinical fellow, clinical instructor, postdoctoral research fellow, postgraduate medical trainee, junior faculty or established investigator. |
About: This clinical pilot award generates hypothesis-driven, clinically focused patient centered research that could improve our understanding of novel therapeutic areas of interest, test interventions, or develop clinical research methodologies. The grant is designed to enable research that has the potential to improve an unmet clinical need relevant to the care of LAM patients. A successful application must be feasible within one year and should have a high probability of generating tangible results, such as larger clinical trials, new approaches to or methods to analyze clinical trials, or new data that could be utilized in a natural history database. | https://www.thelamfoundation.org/investigators/funding-opportunities/ |
| LAM Foundation Pilot and Feasibility Grant | Amount: $100,000 | Deadline: •LOI due June 15, 2026 •Full proposal due September 15, 2026 |
Eligibility: An applicant may be a postdoctoral research fellow, postgraduate medical trainee, junior faculty, or established investigator. The LAM Foundation encourages applications from investigators new to LAM research who could contribute their knowledge and expertise. |
About: This pilot award provides funds to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to LAM. The proposed work must be hypothesis generating or hypothesis testing, reflecting innovative approaches to important questions in LAM research or development of novel methods, and providing sufficient preliminary data to justify the Foundation’s support. Results from Pilot and Feasibility Grants should have the potential to lead to the submission of applications for funding from other agencies (e.g., NIH). The award is not intended to support the continuation of programs initiated under other granting mechanisms. | https://www.thelamfoundation.org/investigators/funding-opportunities/ |
| Research to Prevent Blindness Physician-Scientist Award | Amount: $300,000 over 2 years | Deadline: • Nominations due June 15, 2026 • Full proposal due July 1, 2026 |
Eligibility: Department Chairs (including interim or acting Chairs) from any institution of higher education in the U.S. may nominate multiple candidates per department. Though multiple candidates can be nominated from one department, only one award per department can be approved. Candidates must hold a primary academic position as Associate Professor through full Professor (MD, PhD, or MD/PhD) with a primary appointment in a basic science or other relevant department. Previous recipients of this grant are ineligible. Candidates must be full-time faculty in their primary appointment department. Proposed research cannot be funded – previously or currently – by others (NEI, NIH, nonprofits, private funders, etc.). Candidates declined for this award must wait two years before re-applying for the SI Award. |
About: The RPB Clinician-Scientist Award in Myopia Research will focus on research that seeks to provide a better understanding of the development of myopia and/or how it can be prevented or decelerated. The number of people affected by myopia is now increasing around the world and is projected to affect 50% of the world population by 2050. | https://www.rpbusa.org/grants/ |
| Research to Prevent Blindness Stein Innovation Award | Amount: $300,000 over 2 years | Deadline: • Nominations due June 15, 2026 • Full proposal due July 1, 2026 |
Eligibility: Department Chairs (including interim or acting Chairs) from any institution of higher education in the U.S. may nominate multiple candidates per department. Though multiple candidates can be nominated from one department, only one award per department can be approved. Candidates must hold a primary academic position as Associate Professor through full Professor (MD, PhD, or MD/PhD) with a primary appointment in a basic science or other relevant department. Previous recipients of this grant are ineligible. Candidates must be full-time faculty in their primary appointment department. Proposed research cannot be funded – previously or currently – by others (NEI, NIH, nonprofits, private funders, etc.). Candidates declined for this award must wait two years before re-applying for the SI Award. |
About: The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. For the January deadline, Department of Ophthalmology faculty who are performing innovative vision research may apply for the SI Awards. Candidates may be from any institution of higher education in the U.S. For the July deadline, scientists outside the Department of Ophthalmology who are actively engaged in innovative vision research may apply for the SI Awards. | https://www.rpbusa.org/grants/ |
| Samuel Waxman Institute / Mark Foundation: 2026 Request for Proposals for Aging & Cancer Grants | Amount: Up to $500,000 over 3 years | Deadline: •LOI due June 15, 2026 •Full proposal due September 15, 2026 |
Eligibility: •Applicants must have an independent faculty appointment (tenure-track or equivalent) at a non-profit academic/research institution. •Collaboration teams must consist of one principal investigator (PI) at the host institution and one co-principal investigator (co-PI) at a different institution. We encourage teams that bring together individuals with distinct expertise (e.g. a cancer investigator and computational expert, a cancer investigator and an aging expert who has not previously worked in the cancer field, or experts who study aging in oncology and immunology). •The PI and co-PI must both lead established laboratories currently supported by multi-year independent funding. For example, for US-based applicants, this should be at least one R01 or R01-equivalent grant. International applicants should similarly demonstrate independent support for their labs. •Investigators who currently hold “Aging and Cancer” awards from the Mark Foundation are not permitted to apply. •The PI and co-PI can only participate in one application, regardless of role. |
About: Research supported by this program will advance our understanding of the rising incidence of cancer due to aging, with a special emphasis on the role of inflammaging and immunosenescence as common drivers of aging and cancer. Example topics include but are not limited to: •Identifying actionable biomarkers (inflammatory molecules, immune cells, etc.) that link aging and cancer risk, including in younger individuals with early onset cancers and those with genetic predispositions, and underlying mechanisms. •Dissecting the effects of the aging tumor microenvironment (e.g., inflammation, immune system, senescent cells) on tumorigenesis, progression, and treatment response. •Investigating how progression of age-related clonal hematopoiesis, myeloid skewing, or emergency myelopoiesis promotes hematological malignancies (including chronic myelomonocytic leukemia) or solid tumors, and/or causes therapeutic resistance. •Establishing the effects of tumors and cancer therapies in organismal aging, including the identification of biomarkers and therapeutic strategies to minimize or prevent cancer-induced aging. •Providing preclinical and mechanistic validation for aging-specific, anticancer therapeutic approaches based on strategies targeting inflammation or senescence, or nominated from clinical trial data segregated by age. •Supporting exploratory clinical trials to treat or prevent cancer in older or high-risk individuals, including correlative analyses from clinical samples derived from relevant trials. We encourage collaborations with biopharma or GCO Funding OpportunitiesMonthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page. STAY CONNECTEDSign up for the Research Listserv to stay up to date with the latest news and events. Research 411 PortalStill Need Help? |